Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy

Breast Cancer Research and Treatment

Volumn 54, Issue 3, 1999, Pages 205-212

  Viens, P ^a,c   Jacquemier, J ^a   Bardou, V J ^a   Bertucci, F ^a   Penault Llorca, F ^a   Puig, B ^a   Gravis, G ^a   Oziel Taieb S ^a   Resbeut, M ^a   Houvenaeghel, G ^a   Camerlo, J ^a   Birbaum, D ^b   Hassoun, J ^a   Maraninchi, D ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

Adjuvant chemotherapy; Angiogenesis; Node positive breast cancer; Response

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; HORMONE; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; ALGORITHMS; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0032998739     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006112927565     Document Type: Article

References (40)

1. 1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339(8784): 1-15, 1992
2. 2. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339(8785): 71-85, 1992
3. 3. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85(15): 1206-1219, 1993
4. 4. Perren TJ: c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63: 328-332, 1991
5. 5. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Renderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 330: 1260-1266, 1994
6. 6. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093-1096, 1996
7. 7. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC, Allred DC: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87(16): 1254-1256, 1995
8. 8. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14(5): 1604-1610, 1996
9. 9. Gasparini G, Barbareschi M, Doglioni C, Dalla Palma P, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, Pezzella F, Harris AL: Expression of bcl-2 protein predicts efficacy of adjuvant treatment in operable node-positive breast cancer. Clin Cancer Res 1: 189-198, 1995
10. 10. Fidler IJ, Ellis LM: The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994
11. 11. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995
12. 12. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, Radealli U, Di Bacco A, Guglielmi RB, Bevilacqua P: Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69: 205-211, 1996
13. 13. Fontanini G, Vignati S, Lucchi M, Mussi A, Calcinai A, Boldrini L, Chiné S, Silvestri V, Angeletti CA, Basolo F, Bevilacqua G: Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 75(9): 1295-1301, 1997
14. 14. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13(3): 765-782, 1995
15. 15. Folkman J: The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 36: 109-118, 1995
16. 16. Barinaga M: Designing therapies that target tumor blood vessels. Science 275: 482-484, 1997
17. 17. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: Experience from a large study with long term follow-up. Histopathology 19: 403-410, 1991
18. 18. Jacquemier JD, Charpin C, Martin PM: Etude immunohistochimique par anticorps monoclonal (H222SP gamma) des récepteurs oestrogéniques: Corrélation avec l' analyse biochimique par radioligand pour 115 carcinomas mammaires. Bull Cancer 73: 107-119, 1986
19. 19. Jacquemier JD, Penault-Llorca FM, Bertucci F, Sun ZZ, Houvenaeghel GF, Geneix JA, Puig BD, Bardou VJH, Hassoun JA, Birnbaum D, Viens PJ: Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: A multiparametric and immunohistochemical analysis. J Pathol 184: 130-135, 1998
20. 20. Vermeulen PB, Libura M, Libura J, O'Neill PJ, van Dam P, van Marck E, van Oosterom AT, Dirix LY: Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Res Treat 42: 165-172, 1997
21. 21. Barbareschi M, Weidner N, Gasparini N, Morrelli L, Forti S, Eccher C, Fina P, Caffo O, Leonardi E, Mauri F, Bevilacqua P, Dalla Palma P: Microvessel density quantification in breast carcinomas. Appl Immunohistochem 3: 75-84, 1995
22. 22. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1971
23. 23. Peto R, Peto J: Asymptomatically efficient rank invariant test procedures. J R. Stat Soc A 135: 185-198, 1972
24. 24. Cox DR: Regression models and life table (with discussion). J R Stat Soc B 34: 187-220, 1972
25. 25. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman DR, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11(6): 1132-1143, 1993
26. 26. Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, Salvadori B, Luini A, Greco M, Zucali R, Rilke F, Zambetti M, Valagussa P, Bonadonna G: Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 15(6): 2312-2321, 1997
27. 27. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 324(1): 1-8, 1991
28. 28. Van Hoef MEHM, Knox WF, Dhesi SS, Howell A, Schor AM: Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29A(8): 1141-1145, 1993
29. 29. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12(3): 454-466, 1994
30. 30. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88(23): 1764-1769, 1996
31. 31. Axelsson K, Ljung B-ME, Moore DH II, Thor AD, Chew KL, Edgerton SM, Smith HS, Mayall BH: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87(13): 997-1008, 1995
32. 32. Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55: 371-374, 1993
33. 33. Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992
34. 34. Weidner N, Folkman J, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84(24): 1875-1887, 1992
35. 35. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanaïani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2): 139-147, 1997
36. 36. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res I: 961-964, 1995
37. 37. Protopapa E, Delides GS, Révész L: Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy. Eur J Cancer 29A(10): 1391-1393, 1993
38. 38. Paulsen T, Aas T, Borresen A-L, Verhaug JE, Lonning PE, Akslen LA: Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. Int J Cancer 74: 138-140, 1997
39. 39. Gasparini G, Fox SB, Verderio P, Bonoldi E, Bevilacqua P, Boracchii P, Dante S, Marubini E, Harris AL: Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 2: 1191-1198, 1996
40. 40. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL: Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 89(14): 1044-1049, 1997